腫瘍溶解性ウイルス免疫療法の世界市場

腫瘍溶解性ウイルス免疫療法の世界市場は2030年までに4億2,910万米ドルに達する見込み

2024年に1億5,680万米ドルと推定される腫瘍溶解性ウイルス免疫療法の世界市場は、2030年には4億2,910万米ドルに達し、分析期間2024-2030年のCAGRは18.3%で成長すると予測されます。本レポートで分析したセグメントの1つである単純ヘルペスウイルスは、CAGR 18.6%を記録し、分析期間終了時には1億8,970万米ドルに達すると予測されます。ワクチンウイルスセグメントの成長率は、分析期間中CAGR 15.3%と推定されます。

米国市場は4,270万米ドルと推定、中国はCAGR24.8%で成長予測

米国の腫瘍溶解性ウイルス免疫療法市場は、2024年に4,270万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 24.8％を辿り、2030年には予測市場規模9,970万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.5％と16.3％と予測されています。欧州では、ドイツがCAGR約15.2%で成長すると予測されています。

世界の腫瘍溶解性ウイルス免疫療法市場- 主要動向と促進要因のまとめ

がん免疫療法における破壊的モダリティとしてがん溶解性ウイルスが再浮上している理由とは？

腫瘍溶解性ウイルス免疫療法は、直接的な腫瘍溶解と免疫系のプライミングを組み合わせた二重作用の治療戦略として、腫瘍学で再び勢いを増しています。これらの遺伝子操作された、あるいは自然に発生するウイルスは、腫瘍細胞に選択的に感染・複製し、その破壊を引き起こすと同時に、抗がん免疫応答を刺激する腫瘍関連抗原を放出します。従来の化学療法や放射線療法とは異なり、腫瘍溶解ウイルスは腫瘍部位で局所的に作用し、免疫活性化を通じて全身的に作用するため、固形および血液の両悪性腫瘍において汎用性の高い薬剤として位置づけられています。

1990年代の初期の挫折にもかかわらず、分子ウイルス学、遺伝子編集、免疫腫瘍学の最近の進歩により、このアプローチへの関心が再び高まっています。メラノーマに対するT-VEC（talimogene laherparepvec）が2015年にFDAから承認されたことは画期的な出来事であり、オンコリティックウイルス療法の概念が臨床の場で検証されました。それ以来、膠芽腫、結腸直腸がん、膵臓がん、非小細胞肺がんなど複数のがん種を対象とした臨床試験が急増し、この治療法の範囲と信頼性が拡大しました。単独療法として、あるいはチェックポイント阻害剤との併用療法として、オンコライト・ウイルスは次世代免疫療法レジメンの要になりつつあります。

遺伝子工学と併用プロトコールはどのようにがん溶解性ウイルス療法の可能性を広げているのか？

合成生物学とベクター工学における最近のブレークスルーは、がん溶解ウイルスの安全性、選択性、免疫賦活能力を著しく向上させています。単純ヘルペスウイルス（HSV）、アデノウイルス、ワクシニアウイルス、レオウイルスなどをベースにした新しいウイルスコンストラクトは、GM-CSF、インターロイキン、チェックポイント遮断ペプチドなどの免疫増強導入遺伝子で武装されています。これらの改変により、ウイルスは腫瘍細胞を破壊するだけでなく、腫瘍微小環境（TME）を免疫学的に活性な部位に変えることができます。

併用療法は主要な焦点であり、オンコライトウイルスは耐性メカニズムを克服し、全身的な抗腫瘍反応を増強するために、免疫チェックポイント阻害剤（抗PD-1/PD-L1など）、CAR-T療法、または放射線療法と併用されることが多くなっています。腫瘍内投与法、用量漸増プロトコール、多部位投与戦略により、ウイルスの生体内分布が改善され、オフターゲット効果が減少しています。ウイルスの持続性、免疫浸潤、治療反応をリアルタイムでモニターするためのリキッドバイオプシーや画像バイオマーカーの開発も進んでいます。このような進歩により、腫瘍溶解性ウイルス療法はニッチな治療法からマルチモーダルながん治療の枠組みに不可欠な要素へと移行しつつあります。

どのような腫瘍の種類と地域が、がん溶解ウイルスの臨床的・商業的展望を形成しているか？

メラノーマ、神経膠芽腫、膵臓がん、肝細胞がんなど、免疫抑制性の微小環境を有する固形がんは、腫瘍溶解性ウイルス療法の有力な候補です。これらのがんは通常、従来の治療法に対する反応が乏しく、T細胞の浸潤が欠如していることが多いが、オンコリティック・ウイルスはこれを克服するのに役立ちます。リンパ腫や多発性骨髄腫のような血液悪性腫瘍も、自然免疫と適応免疫の両方に作用することができる人工ウイルスによって標的化されつつあります。

北米が臨床開発をリードしており、米国が初期段階および主要臨床試験の大半を実施しています。主要なウイルス療法開発企業の存在、強固な資金調達エコシステム、イノベーションに優しい規制環境が、トランスレーショナルな進展を加速しています。欧州は、強力な産学連携とEMAの先進治療薬（ATMP）指定による規制支援でこれに続きます。アジア太平洋は競合情勢として台頭してきており、特に中国ではバイオテクノロジー企業がオンコリティック・プラットフォームに多額の投資を行っており、規制改革により迅速な試験開始が可能となっています。世界のがんセンターでは、オンコロティックウイルスをコンパッショネートユースプログラムや併用試験プロトコールに組み込む動きが加速しています。

腫瘍溶解性ウイルス免疫療法市場の長期的成長と科学的革新の原動力は何か？

腫瘍溶解性ウイルス免疫療法市場の成長の原動力は、免疫主導のがん制御へのパラダイムシフト、難治性腫瘍の発生率の上昇、遺伝子改変生物学的製剤に対する規制当局の開放性の高まりです。がん細胞溶解ウイルスは、カスタマイズ可能なペイロードとデリバリー・オプションを備えたプラットフォーム・アプローチを提供し、進化する免疫腫瘍学的ランドスケープへの適応性を高めています。腫瘍を低温から高温に変換するウイルスの能力は、今日のがん免疫療法における最大の課題のひとつに対処しています。

製薬会社は、アカデミックなウイルス学者、バイオテクノロジー企業、臨床腫瘍学ネットワークとのコラボレーションを通じて研究開発を加速させています。AIを活用したウイルスベクター設計、CRISPRを活用した導入遺伝子統合、腫瘍内微量投与技術により、特異性と安全性プロファイルが向上しています。スケーラブルな製造、凍結乾燥製剤、コールドチェーンロジスティクスへの投資は、より広範な市場への対応を支援しています。個別化がんワクチンや免疫細胞療法が普及するにつれ、腫瘍溶解性ウイルスは自然免疫と適応免疫の橋渡しをする免疫増幅器としての役割を果たすようになってきています。がん免疫療法の未来は、こうしたプログラム可能で自己増幅し、免疫感作を行うウイルス剤によってますます形作られていくと思われます。

セグメント

タイプ（単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他のタイプ）、投与ルート（腫瘍内ルート、静脈内ルート）、アプリケーション（メラノーマアプリケーション、非小細胞肺がんアプリケーション、膵臓がんアプリケーション、乳がんアプリケーション、その他のアプリケーション）

調査対象企業の例（注目の41社）

• Amgen Inc.
• CG Oncology
• Creative Biolabs
• Daiichi Sankyo Co., Ltd.
• Genelux Corporation
• ImmVirX
• Imugene Limited
• Lokon Pharma AB
• Merck & Co., Inc.
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Oncorus Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Sorrento Therapeutics, Inc.
• Syneos Health, Inc.
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Viralytics Ltd.
• ViraTherapeutics GmbH

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Oncolytic Virus Immunotherapy Market to Reach US$429.1 Million by 2030

The global market for Oncolytic Virus Immunotherapy estimated at US$156.8 Million in the year 2024, is expected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$189.7 Million by the end of the analysis period. Growth in the Vaccinia Virus segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.7 Million While China is Forecast to Grow at 24.8% CAGR

The Oncolytic Virus Immunotherapy market in the U.S. is estimated at US$42.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$99.7 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.5% and 16.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Global Oncolytic Virus Immunotherapy Market - Key Trends & Drivers Summarized

Why Are Oncolytic Viruses Re-emerging as a Disruptive Modality in Cancer Immunotherapy?

Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.

Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types-including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer-has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.

How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?

Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs-based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus-are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.

Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.

Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?

Solid tumors with immunosuppressive microenvironments-such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma-are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.

North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.

What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?

The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.

Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Amgen Inc.
• CG Oncology
• Creative Biolabs
• Daiichi Sankyo Co., Ltd.
• Genelux Corporation
• ImmVirX
• Imugene Limited
• Lokon Pharma AB
• Merck & Co., Inc.
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Oncorus Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Sorrento Therapeutics, Inc.
• Syneos Health, Inc.
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Viralytics Ltd.
• ViraTherapeutics GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Oncolytic Virus Immunotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Focus on Precision Oncology Spurs Development of Oncolytic Virus Platforms With Tumor Selectivity
  • Expansion of Immunotherapy Research Pipelines Strengthens Business Case for Oncolytic Virus Modalities
  • Increased Approval of Cancer Immunotherapies Throws the Spotlight on Next-Generation Viral Vectors
  • Breakthrough Designation Status and Fast Track Approvals Accelerate Regulatory Momentum
  • Advancements in Genetic Engineering of Viruses Drive Enhanced Tumor Targeting and Immune Activation
  • Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expands Therapeutic Horizons
  • Increased Use of Oncolytic Viruses as Neoadjuvant Therapies Supports Multimodal Cancer Management
  • Growing Investment From Biopharma and Venture Capital Enhances Innovation and Clinical Translation
  • Development of Tumor-Specific Viral Payloads Strengthens Oncolytic Virus Selectivity and Safety Profiles
  • Adoption of Intratumoral and Systemic Delivery Routes Expands Accessibility to Diverse Tumor Types
  • Improved Understanding of Tumor Microenvironment Enhances Viral Mechanism Optimization
  • Collaborative Efforts Between Academia and Industry Propel Translational Research in Viral Oncology
  • Expansion of Cold Chain Logistics Infrastructure Supports Global Supply of Virus-Based Therapies
  • Public and Philanthropic Funding for Rare Cancer Treatment Drives Orphan Application Development
  • Manufacturing Scale-Up of Viral Vectors Remains a Bottleneck for Commercialization Readiness
  • Development of Immune Response Biomarkers Facilitates Patient Selection and Treatment Monitoring
  • Increased Advocacy for Personalized Cancer Immunotherapy Supports Patient Enrollment in Viral Trials
  • Challenges in Viral Shedding and Immunogenicity Highlight Need for Improved Safety Profiling
  • Rising Global Cancer Incidence and Limited Success in Refractory Cancers Propel Need for Disruptive Modalities
  • Regulatory Alignment on Gene and Virus Therapies Enhances Global Clinical Trial Harmonization
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oncolytic Virus Immunotherapy Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Vaccinia Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Reovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pancreatic Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pancreatic Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Non-small Cell Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Non-small Cell Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Intratumoral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Intratumoral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• JAPAN
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• CHINA
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• EUROPE
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• FRANCE
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• GERMANY
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• INDIA
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Oncolytic Virus Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030
• AFRICA
  • Oncolytic Virus Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Oncolytic Virus Immunotherapy by Type - Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus and Other Types for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Oncolytic Virus Immunotherapy by Application - Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Application - Percentage Breakdown of Value Sales for Pancreatic Cancer Application, Breast Cancer Application, Other Applications, Melanoma Application and Non-small Cell Lung Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Oncolytic Virus Immunotherapy by Administration Route - Intratumoral Route and Intravenous Route Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Oncolytic Virus Immunotherapy by Administration Route - Percentage Breakdown of Value Sales for Intratumoral Route and Intravenous Route for the Years 2015, 2025 & 2030

IV. COMPETITION